Els investigadors del grup de recerca en sarcomes de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) han testat en 19 pacients una nova combinaci\u00f3 terap\u00e8utica per lluitar contra els sarcomes resistents. Els resultats de l\u2019assaig cl\u00ednic, que indiquen que el nou tractament podria estabilitzar el creixement d\u2019aquests tumors, s\u2019han publicat aquesta setmana a la revista British Journal of Cancer.<\/p>\n
Els sarcomes s\u00f3n un tipus de tumor poc freq\u00fcent i complex ja qu\u00e8 existeixen diversos subtipus. Pot afectar des de nens fins a edats avan\u00e7ades. S\u2019acostuma a diagnosticar en fases poc avan\u00e7ades i molt localitzades. De forma que el 50% es cura amb grans cirurgies i tractament localitzat. Per\u00f2 l\u2019altre 50% es fa resistent a les ter\u00e0pies convencionals i acaba fent met\u00e0stasi.<\/p>\n
El grup de recerca en sarcomes de l\u2019IDIBELL, liderat per \u00d2scar Mart\u00ednez-Tirado, investiga per provar nous f\u00e0rmacs o noves combinacions de f\u00e0rmacs que siguin m\u00e9s efica\u00e7os contra aquests tumors i per aix\u00f2 treballa de forma conjunta amb el coordinador de la Unitat de sarcomes de l\u2019ICO, Javier Garc\u00eda del Muro. Aquest treball en equip de la recerca m\u00e9s b\u00e0sica a la m\u00e9s cl\u00ednica ha perm\u00e8s en aquest cas poder portar els resultats de la recerca del laboratori al llit del pacient.<\/p>\n
Els investigadors van provar diferents combinacions de quimioter\u00e0pia convencional amb nous f\u00e0rmacs dirigits a dianes moleculars al laboratori en c\u00e8l\u00b7lules de sarcomes i van decidir provar en ratolins una combinaci\u00f3 de la quimioter\u00e0pia convencional que s\u2019utilitza per tractar aquests tumors i rapamicina, un f\u00e0rmac que actua de forma espec\u00edfica en la via de mTOR, una prote\u00efna alterada en diversos tipus de c\u00e0ncer.<\/p>\n
\u201cAmb els resultats en les l\u00ednees cel\u00b7lulars vam pensar que era la millor opci\u00f3 per provar en ratolins\u201d ha explicat Mart\u00ednez-Tirado \u201cper\u00f2 la veritat \u00e9s que els resultats en animals van ser espectaculars. En els ratolins que presentaven el tumor i els don\u00e0vem aquesta combinaci\u00f3, el tumor deixava de cr\u00e9ixer i setmanes despr\u00e9s de parar el tractament, no es recuperava com passa si els tractem o b\u00e9 nom\u00e9s amb la quimioter\u00e0pia o nom\u00e9s amb la rapamicina\u201d. El responsable d\u2019aquest assaig cl\u00ednic en fase I ha estat Javier Garcia del Muro que ha testat aquesta nova combinaci\u00f3 en dinou pacients, la majoria de sarcoma per\u00f2 tamb\u00e9 van participar pacients amb altres tipus de tumors que no tenen tractament. \u201cTot i que els assaigs en fase I serveixen per determinar la dosi recomanada del nou tractament i descartar toxicitats, s\u00ed que hem vist que la combinaci\u00f3 \u00e9s activa en diversos tipus tumorals, ja qu\u00e8 hem vist estabilitzacions molt prolongades en tumors molt avan\u00e7ats i resistents a la quimioter\u00e0pia\u201d.<\/p>\n
Amb aquests resultats esperan\u00e7adors, el grup ja ha posat en marxa la fase II de l\u2019assaig cl\u00ednic. \u201cHem acabat el reclutament de pacients, en aquest cas, nom\u00e9s de sarcomes, per testar si realment aquesta combinaci\u00f3 funciona en aquests pacients i si \u00e9s millor que els tractaments actuals\u201d.<\/p>\n
<\/p>\n
<\/p>\n
Refer\u00e8ncia de l’article
\nJuan Martin-Liberal, Marta Gil-Mart\u00edn, Miguel S\u00e1inz-Jaspeado, Nuria Gonzalo, Raul Rigo, Helena Colom, Carmen Mu\u00f1oz, Oscar M Tirado and Xavier Garc\u00eda del Muro. Phase I study of sirolimus plus gemcitabine in solid tumors. British Journal of Cancer. Epub ahead July 8th.<\/p>\n","protected":false},"excerpt":{"rendered":"
Els investigadors del grup de recerca en sarcomes de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i de l\u2019Institut Catal\u00e0 d\u2019Oncologia (ICO) han testat en 19 pacients una nova combinaci\u00f3 terap\u00e8utica per lluitar contra els sarcomes resistents. Els resultats de l\u2019assaig cl\u00ednic, que indiquen que el nou tractament podria estabilitzar el creixement d\u2019aquests tumors, s\u2019han publicat […]<\/p>\n","protected":false},"author":6,"featured_media":10992,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,332,447,398],"tags":[],"class_list":["post-8335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-sarcoma"],"publishpress_future_action":{"enabled":false,"date":"2024-12-31 02:20:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8335"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8335\/revisions"}],"predecessor-version":[{"id":19646,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8335\/revisions\/19646"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10992"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}